Mercator Medical expects higher margins: Mercator Medical stock is valued at PLN 539.5 million

Published on 10/15/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mercator Medical expects higher margins after October 6 comments. Mercator Medical stock stood at EUR 13.52 on October 15, 2026, at PLN 539.5 million value.

Operating outlook and results

Mercator Medical outlined a PLN 51.0 million Thailand investment on October 6, 2026.
First-half sales reached PLN 337.2 million in 2026, up 16 percent year over year.
Mercator Medical stock stood at EUR 13.52 at 1:16 p.m. CEST at Lang & Schwarz on October 15, 2026.

Mercator Medical, PLMRCTR00015, Illustration mit AI erstellt.

Mercator Medical (ISIN PLMRCTR00015) stood at EUR 13.52 at Lang & Schwarz on October 15, 2026 at 1:16 p.m. CEST, while its market capitalization was PLN 539.5 million. The latest company outlook points to higher margins in distribution and Thai manufacturing, but raw-material costs remain a pressure point.

According to BIZNES24 on October 6, 2026, Chief Executive Monika ?yznowska expected distribution and Thai production margins to stay above 2025 levels. Chief Financial Officer Mariusz Popek said a cogeneration project costing PLN 51.0 million was in its final acceptance stage.

What does the margin plan mean for costs?

The Thailand project is designed to reduce outside electricity purchases by up to 95 percent, according to BIZNES24. The same October 6 report said nitrile costs were over 25 percent higher than in the first half, leaving the production segment exposed even as demand stabilizes.

Three dates show the earnings recovery

On June 30, 2026, shareholders approved a total dividend allocation of PLN 15.0 million, including PLN 6.1 million from 2025 profit, according to Mercator Medical. On September 30, 2026, the half-year report showed PLN 337.2 million of sales and PLN 61.4 million of EBITDA, compared with PLN 290.9 million and negative PLN 0.7 million a year earlier, as reported by BiznesRadar. On October 6, 2026, management linked the expected margin resilience to automation, cost optimization and the Thailand cogeneration project.

Stock value and operating context

The first-half figures provide the central comparison for Mercator Medical stock. Sales increased 16 percent year over year, while net profit rose to PLN 57.7 million from PLN 21.4 million, according to Mercator Medical. The United States generated PLN 136.8 million of sales and represented 40.6 percent of group revenue in the first half, adding geographic support to the margin story.

Mercator Medical stock remains tied to margins

At EUR 13.52 at Lang & Schwarz on October 15, 2026 at 1:16 p.m. CEST, the stock price gives investors a live euro reference while the operating case rests on the PLN 337.2 million first-half sales base and the planned energy savings.

The further course of trading is shown by the continuously updated real-time quote of Mercator Medical stock.